
Syros Pharmaceuticals (NASDAQ:SYRS) brought in sales totaling $5.47 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 5.6%, resulting in a loss of $25.15 million. Syros Pharmaceuticals collected $7.80 million in revenue during Q4, but reported earnings showed a $23.81 million loss.